维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

12篇 您的检索式：作者名="HOLLMIG K"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis显示文摘	van Rhee F Bolejaek V Hollmig K	2007	Blood2007，110，3：	1
	2	Recognition of non- self-polysaccharides by C-type lectin receptors dectin-1 and dectin-2显示文摘	Hollmig ST Ariizumi K Cruz PD Jr	2009	Glycobiology2009，19，6：	1
	3	Recognition of non-self-polysaccharides by C-type lectin receptors dectin- 1 and dectin-2显示文摘	Hollmig ST Ariizumi K Cruz PD	2009	Glycobiology2009，19，6：	1
	4	Recognition of nonself-polysaccharides by C-type lectin receptors dectin-1 and dectin-2显示文摘	Hollmig ST Ariizumi K Cruz PD Jr		0，，：	1
	5	High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis 显示文摘	van Rhee F Bolejack V Hollmig K	2007	Blood2007，110，：	1
	6	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis 显示文摘	VAN RHEE F BOLEJACK V HOLLMIG K	2007	Blood2007，110，3：	1
	7	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive muhiple myeloma subtype with poor prognosis 显示文摘	van Rhee F Bolejack V Hollmig K	2007	Blood2007，110，3：	1
	8	Addition of bortezomib(Velcade) to high dose melphalan(Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma(MM)显示文摘	HOLLMIG K STOVE J TALAMO G	2004	Blood2004，104，：	1
	9	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis显示文摘	van Rhee F Bolejack V Hollmig K	2007	Blood2007，110，3：	1
	10	Addition of bortezomib(Velcade) to high dose melphalan (Vel- Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM)显示文摘	Hollmig K Stove J Talamo G	2004	Blood2004，104，：	1
	11	High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis 显示文摘	van Rhee F Bolejack V Hollmig K	2007	Blood2007，110，3：	1
	12	Bortezomib(Velcade) + adriamycin + thalidomide + dexamethasome(VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma显示文摘	Hollmig K Stover J Talamo G	2004	Blood2004，104，11：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费